Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of her2 status in breast cancer

Aaron Mansfield, William R. Sukov, Jeanette E Eckel-Passow, Yuta Sakai, Frank J. Walsh, Melissa Lonzo, Anne E. Wiktor, Ahmet Dogan, Robert Brian Jenkins

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The determination of HER2 amplification is critical to selecting appropriate patients for HER2 targeted therapy in breast cancer. Dual in situ hybridization (DISH), an alternative to fluorescence in situ hybridization (FISH) and immunohistochemistry, is now available. To compare the FISH and DISH methods, we tested 251 samples enriched for common or difficult-to-assess HER2 anomalies. Seven samples failed DISH testing. There was a 64% (156/244) concordance between FISH and DISH by anomaly (? = 0.58, 95% confidence interval, 0.51-0.65; P < .0001) and an 83% (203/244) concordance by amplification status (k = 0.58; 95% confidence interval, 0.47-0.69; P < .0001). DISH resulted in lower estimates of HER2/ centromere 17 ratios than FISH, and many cases that were equivocal with FISH were normal with DISH. DISH did not detect any case with coamplification of HER2 and centromere 17. Using a cohort of difficult specimens, we observed less than 95% concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio.

Original languageEnglish (US)
Pages (from-to)144-150
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume139
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
Centromere
Confidence Intervals
Chromosomes, Human, Pair 17
In Situ Hybridization
Immunohistochemistry

Keywords

  • Breast cancer
  • HER2
  • In situ hybridization

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of her2 status in breast cancer. / Mansfield, Aaron; Sukov, William R.; Eckel-Passow, Jeanette E; Sakai, Yuta; Walsh, Frank J.; Lonzo, Melissa; Wiktor, Anne E.; Dogan, Ahmet; Jenkins, Robert Brian.

In: American Journal of Clinical Pathology, Vol. 139, No. 2, 02.2013, p. 144-150.

Research output: Contribution to journalArticle

@article{d8c0cba34a1d49009925aa8ed3a7ee55,
title = "Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of her2 status in breast cancer",
abstract = "The determination of HER2 amplification is critical to selecting appropriate patients for HER2 targeted therapy in breast cancer. Dual in situ hybridization (DISH), an alternative to fluorescence in situ hybridization (FISH) and immunohistochemistry, is now available. To compare the FISH and DISH methods, we tested 251 samples enriched for common or difficult-to-assess HER2 anomalies. Seven samples failed DISH testing. There was a 64{\%} (156/244) concordance between FISH and DISH by anomaly (? = 0.58, 95{\%} confidence interval, 0.51-0.65; P < .0001) and an 83{\%} (203/244) concordance by amplification status (k = 0.58; 95{\%} confidence interval, 0.47-0.69; P < .0001). DISH resulted in lower estimates of HER2/ centromere 17 ratios than FISH, and many cases that were equivocal with FISH were normal with DISH. DISH did not detect any case with coamplification of HER2 and centromere 17. Using a cohort of difficult specimens, we observed less than 95{\%} concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio.",
keywords = "Breast cancer, HER2, In situ hybridization",
author = "Aaron Mansfield and Sukov, {William R.} and Eckel-Passow, {Jeanette E} and Yuta Sakai and Walsh, {Frank J.} and Melissa Lonzo and Wiktor, {Anne E.} and Ahmet Dogan and Jenkins, {Robert Brian}",
year = "2013",
month = "2",
doi = "10.1309/AJCP13GJAOJAYJMW",
language = "English (US)",
volume = "139",
pages = "144--150",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of her2 status in breast cancer

AU - Mansfield, Aaron

AU - Sukov, William R.

AU - Eckel-Passow, Jeanette E

AU - Sakai, Yuta

AU - Walsh, Frank J.

AU - Lonzo, Melissa

AU - Wiktor, Anne E.

AU - Dogan, Ahmet

AU - Jenkins, Robert Brian

PY - 2013/2

Y1 - 2013/2

N2 - The determination of HER2 amplification is critical to selecting appropriate patients for HER2 targeted therapy in breast cancer. Dual in situ hybridization (DISH), an alternative to fluorescence in situ hybridization (FISH) and immunohistochemistry, is now available. To compare the FISH and DISH methods, we tested 251 samples enriched for common or difficult-to-assess HER2 anomalies. Seven samples failed DISH testing. There was a 64% (156/244) concordance between FISH and DISH by anomaly (? = 0.58, 95% confidence interval, 0.51-0.65; P < .0001) and an 83% (203/244) concordance by amplification status (k = 0.58; 95% confidence interval, 0.47-0.69; P < .0001). DISH resulted in lower estimates of HER2/ centromere 17 ratios than FISH, and many cases that were equivocal with FISH were normal with DISH. DISH did not detect any case with coamplification of HER2 and centromere 17. Using a cohort of difficult specimens, we observed less than 95% concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio.

AB - The determination of HER2 amplification is critical to selecting appropriate patients for HER2 targeted therapy in breast cancer. Dual in situ hybridization (DISH), an alternative to fluorescence in situ hybridization (FISH) and immunohistochemistry, is now available. To compare the FISH and DISH methods, we tested 251 samples enriched for common or difficult-to-assess HER2 anomalies. Seven samples failed DISH testing. There was a 64% (156/244) concordance between FISH and DISH by anomaly (? = 0.58, 95% confidence interval, 0.51-0.65; P < .0001) and an 83% (203/244) concordance by amplification status (k = 0.58; 95% confidence interval, 0.47-0.69; P < .0001). DISH resulted in lower estimates of HER2/ centromere 17 ratios than FISH, and many cases that were equivocal with FISH were normal with DISH. DISH did not detect any case with coamplification of HER2 and centromere 17. Using a cohort of difficult specimens, we observed less than 95% concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio.

KW - Breast cancer

KW - HER2

KW - In situ hybridization

UR - http://www.scopus.com/inward/record.url?scp=84875069123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875069123&partnerID=8YFLogxK

U2 - 10.1309/AJCP13GJAOJAYJMW

DO - 10.1309/AJCP13GJAOJAYJMW

M3 - Article

C2 - 23355198

AN - SCOPUS:84875069123

VL - 139

SP - 144

EP - 150

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -